Working... Menu

Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients (OKN-007)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT01672463
Recruitment Status : Recruiting
First Posted : August 24, 2012
Last Update Posted : August 31, 2018
Information provided by (Responsible Party):
Oblato, Inc.

Brief Summary:
This is an open label Phase 1b clinical trial of IV administration of OKN-007 in a pilot cohort of human recurrent malignant glioma patients. All patients will have been previously treated with the standard-of-care treatment which includes surgical resection, radiation and chemotherapy, and in some cases treatment for recurrent disease with investigational agents or bevacizumab (Avastin). Patients with unequivocal recurrence (first or greater) established by MRI with and without contrast (e.g., Gd-DTPA (Gadolinium-diethylene triamine pentacetic acid) and meeting inclusion and exclusion criteria, will be eligible for OKN-007 treatment on this protocol.

Condition or disease Intervention/treatment Phase
Recurrent Malignant Glioma Drug: OKN-007 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 31 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1b Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients
Study Start Date : December 2012
Estimated Primary Completion Date : September 2019
Estimated Study Completion Date : November 2019

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: All patients
All participants enrolled in this study
Drug: OKN-007

Dose escalation/PK cohort: 20 mg/kg, 40 mg/kg or 60 mg/kg OKN-007 via IV infusion, given 3x/week for the first 4 weeks, then 2x/week for the next 4 weeks, then 1x/week thereafter.

Expansion cohort: MTD via IV infusion given 3x/week for the first 4 weeks, then 2x/week for the next 4 weeks, then 1x/week thereafter.

Primary Outcome Measures :
  1. Number of Adverse events per patient [ Time Frame: 24 months ]
    The primary objective is to determine MTD, tolerance, and safety of OKN-007 in patients with recurrent GBM and anaplastic glioma.

Secondary Outcome Measures :
  1. PK level in participants [ Time Frame: 24 months ]
    To determine drug levels of OKN-007 in blood.

  2. 6 month progression-free survival [ Time Frame: 24 months ]
    To determine radiographic response rate and 6 month Progression-Free Survival (PFS) of patients treated with OKN-007. PFS is defined as the time from first drug treatment until objective tumor progression or death.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Confirmed histopathology of WHO grade III glioma or WHO grade IV GBM at primary diagnosis
  2. Unequivocal radiographic evidence of tumor progression by MRI within 14 days prior to registration
  3. Prior radiotherapy
  4. Prior Temozolomide treatment
  5. Last cytotoxic chemotherapy 28 or more days or biologic therapy treatment 14 or more days before study start (greater than or equal to 42 days if nitrosourea was administered)
  6. Karnofsky performance status greater than or equal to 60%
  7. Full recovery (< grade 1) from the toxic effects of any earlier intervention and a minimum of 28 days from the administration of any investigational agent
  8. Adequate renal, liver and bone marrow function:

    • Leukocytes >3,000/mcL
    • Absolute neutrophil count >1,500/mcL
    • Platelets >100,000/mcL
    • Total bilirubin within normal limits
    • AST / ALT (SGPT) <2.5 x ULN
    • Creatinine within normal limits
  9. Patients must be >_18 years of age

Exclusion Criteria:

  1. Second primary malignancy (except adequately treated basal cell carcinoma of the skin). Patients who had another malignancy in the past, but have been free of active disease for more than 2 years, are eligible
  2. Have received treatment within the last 28 days with a drug that has not received regulatory approval for any indication at the time of study entry
  3. Serious concomitant systemic disorders (for example, active infection or abnormal electrocardiogram (ECG) indicative of cardiac disease) that, in the opinion of the investigator, would compromise the safety of the patient and his/her ability to complete the study
  4. Patients with moderate or severe renal impairment (calculated creatinine clearance of < 60 mL/min)
  5. Patients with sodium, potassium, or creatinine serum electrolytes > grade 2.
  6. Patients with PT/PTT above the upper limit of normal
  7. Screening ECG abnormality documented by the investigator as medically significant

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01672463

Layout table for location contacts
Contact: Dena Suthers, RN 405-271-8001 ext 48971

Layout table for location information
United States, Oklahoma
Oklahoma University Recruiting
Oklahoma City, Oklahoma, United States, 73104
Contact: Dena Suthers, RN    405-271-8001 ext 48971      
Principal Investigator: James Battiste, MD, PhD         
Sponsors and Collaborators
Oblato, Inc.
Layout table for investigator information
Principal Investigator: James Battiste, MD, PhD • Oklahoma University

Layout table for additonal information
Responsible Party: Oblato, Inc. Identifier: NCT01672463     History of Changes
Other Study ID Numbers: HCI57337
First Posted: August 24, 2012    Key Record Dates
Last Update Posted: August 31, 2018
Last Verified: August 2018

Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue